Editas Medicine Announces Second Quarter 2017 Results and Update – Nasdaq
NasdaqEditas Medicine Announces Second Quarter 2017 Results and UpdateNasdaqStrengthened unmatched intellectual property position with issuance of first patent for CRISPR/Cpf1. In May, the European Patent Office issued the first patent for CRISPR/Cpf1,… Continue reading
